Inhibition of kynurenine aminotransferase II attenuates hippocampus‐dependent memory deficit in adult rats treated prenatally with kynurenine. Issue 2 (4th December 2018)

• Record Type: Journal Article
• Authors: Pocivavsek, Ana; Elmer, Greg I.; Schwarcz, Robert
• Is Part Of: Hippocampus. Volume 29:Issue 2(2019)
• Page Start: 73
• Page End: 77
• Publication Date: 2018-12-04
• Subjects: consolidation -- glutamate -- kynurenic acid -- neurodevelopment -- schizophrenia; Hippocampus (Brain) -- Periodicals; 612.825
• DOI: 10.1002/hipo.23040
• Languages: English
• ISSNs: 1050-9631

Abstract

Abstract: A combination of genetic and environmental factors contributes to schizophrenia (SZ), a catastrophic psychiatric disorder with a hypothesized neurodevelopmental origin. Increases in the brain levels of the tryptophan metabolite kynurenic acid (KYNA), an endogenous antagonist of α7 nicotinic acetylcholine and NMDA receptors, have been implicated specifically in the cognitive deficits seen in persons with SZ. Here we evaluated this role of KYNA by adding the KYNA precursor kynurenine (100 mg/day) to chow fed to pregnant rat dams from embryonic day (ED) 15 to ED 22 (control: ECon; kynurenine treated: EKyn). Upon termination of the treatment, all rats received normal rodent chow until the animals were evaluated in adulthood (postnatal days 56–85). EKyn treatment resulted in increased extracellular KYNA and reduced extracellular glutamate in the hippocampus, measured by in vivo microdialysis, and caused impairments in hippocampus‐dependent learning in adult rats. Acute administration of BFF816, a systemically active inhibitor of kynurenine aminotransferase II (KAT II), the major KYNA‐synthesizing enzyme in the brain, normalized neurochemistry and prevented contextual memory deficits in adult EKyn animals. Collectively, these results demonstrate that acute inhibition of KYNA neosynthesis can overcome cognitive impairments that arise as a consequence of elevated brain KYNA in early brain development.